Trials / Recruiting
RecruitingNCT07138196
A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease
A Phase 1b, Open-label Dose Escalation Study to Evaluate the Safety, Pharmacodynamic, Pharmacokinetic and Preliminary Efficacy of Q702 in Subjects With Relapsed or Refractory Active Chronic Graft-versus-Host Disease (cGVHD)
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Qurient Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Open-label, dose escalation study to evaluate safety, tolerability pharmacokinetic and pharmacodynamic activity, and efficacy of Adrixetinib (Q702) in subjects with relapsed or refractory active chronic graft-versus-host disease (cGVHD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adrixetinib | Administered orally |
Timeline
- Start date
- 2025-12-23
- Primary completion
- 2029-10-23
- Completion
- 2029-10-31
- First posted
- 2025-08-22
- Last updated
- 2025-12-30
Locations
8 sites across 1 country: Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07138196. Inclusion in this directory is not an endorsement.